Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
About BioCorRx Inc. (BICX)
BioCorRx Inc. (OTCQB: BICX) is a pioneering healthcare solutions company dedicated to addressing the critical public health challenges of addiction and obesity through innovative treatment programs and clinical-stage pharmaceutical development. Headquartered in Anaheim, California, BioCorRx operates at the intersection of addiction treatment, behavioral health, and pharmaceutical innovation, offering a comprehensive suite of solutions aimed at improving patient outcomes and quality of life.
Core Business Areas
BioCorRx’s business is centered on two primary domains:
- Substance Use Disorder (SUD) Treatment: The company’s flagship offering, the BioCorRx® Recovery Program, combines a proprietary long-acting naltrexone implant with cognitive behavioral therapy (CBT) modules and peer support. This program is designed to significantly reduce cravings for alcohol and opioids, addressing the root causes of addiction while providing patients with the tools and support needed for sustainable recovery.
- Weight Loss Solutions: The UnCraveRx® Weight Loss Program incorporates medication-assisted therapy with behavioral and nutritional counseling, offering a holistic approach to combating obesity. This program leverages the company’s expertise in addiction treatment to address the behavioral aspects of weight management.
Pharmaceutical Innovation
Through its majority-owned subsidiary, BioCorRx Pharmaceuticals Inc., the company is advancing clinical-stage drug development with a focus on implantable, long-acting naltrexone therapies. The flagship product under development, BICX104, is a biodegradable naltrexone pellet designed for subcutaneous implantation. This innovative treatment aims to improve patient compliance by providing sustained therapeutic levels of naltrexone for up to 84 days, significantly reducing the risk of relapse in opioid and alcohol use disorders. BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA) under the NIH HEAL Initiative®, further underscoring the company’s commitment to addressing the opioid crisis.
Market Position and Differentiation
BioCorRx operates in a competitive landscape that includes traditional rehabilitation centers, pharmaceutical companies, and behavioral health providers. The company sets itself apart through its integrated approach, which combines FDA-approved medications, proprietary delivery systems, and evidence-based behavioral therapies. Its focus on long-acting, implantable treatments addresses common challenges in addiction recovery, such as medication adherence and patient compliance, offering a unique value proposition in the market.
Strategic Partnerships and Funding
BioCorRx has secured significant funding and partnerships to advance its mission. Notably, the company received a multi-year grant from NIDA to accelerate the development of BICX104 for methamphetamine use disorder (MUD), a condition with no currently approved medications. This collaboration highlights BioCorRx’s role as a trusted partner in addressing unmet medical needs and its ability to leverage external resources to drive innovation.
Commitment to Public Health
Beyond its commercial pursuits, BioCorRx is deeply committed to tackling pressing public health issues. Its programs are designed not only to treat addiction and obesity but also to alleviate the broader societal impacts of these conditions, such as healthcare costs, lost productivity, and the emotional toll on families and communities.
Future Outlook
With a robust pipeline of innovative treatments, a growing intellectual property portfolio, and strategic collaborations with leading institutions, BioCorRx is well-positioned to make a lasting impact on the fields of addiction treatment and behavioral health. The company’s ongoing efforts to secure FDA approval for BICX104 and expand its weight loss program reflect its commitment to addressing unmet medical needs and improving patient outcomes worldwide.
BioCorRx Inc. (OTCQB: BICX) provided a business update for Q3 2021, highlighting progress in its FDA drug approval process for BICX104, an implantable pellet for opioid use disorder. The company secured approximately $3.5 million in non-dilutive funding from the National Institute on Drug Abuse (NIDA), aiding their FDA submission efforts. An agreement with IriSys LLC was expanded for manufacturing support. Additionally, BioCorRx filed patent applications in the U.S. and Russia for BICX104, furthering its intellectual property strategy.
BioCorRx Inc. (OTCQB: BICX) announced the filing of a patent application with the Russian Patent Office for a biodegradable naltrexone implant aimed at treating opioid use disorder (OUD). The application focuses on BICX104, an implantable pellet developed by BioCorRx Pharmaceuticals, the company's R&D subsidiary. CEO Lourdes Felix emphasized the company’s commitment to addressing the global opioid crisis, particularly in Russia, where drug use affects around 6% of the population. BioCorRx has received FDA clearance to start human trials for BICX104, funded significantly by the National Institute on Drug Abuse.
BioCorRx Inc. (OTCQB: BICX) will present at LD Micro’s 14th annual Main Event on October 12, 2021, at 1:30 PM PT in Los Angeles. CEO Lourdes Felix and Brady Granier will represent the company during the event, which aims to feature about 150 companies. The conference will be held from October 12 to 14, 2021, showcasing investor presentations and keynotes. BioCorRx specializes in innovative solutions for substance use disorders, including the Beat Addiction Recovery program and UnCraveRx® for weight loss.
BioCorRx Inc. (OTCQB: BICX) has filed a patent application for a biodegradable implant containing naltrexone, specifically targeting opioid use disorder (OUD) with its product BICX104. The FDA has cleared the company to begin human trials for this drug candidate. Funding for the project is significantly provided by a $3.5 million non-dilutive grant from the National Institute on Drug Abuse (NIDA). CEO Lourdes Felix expressed optimism about advancing BICX104 towards FDA approval as the company prepares for the first-in-human clinical trial.
Recro Pharma and BioCorRx have expanded their partnership through a new development and manufacturing agreement. Recro will provide analytical validation services and cGMP manufacturing of registrational batches of BICX104 to support its New Drug Application (NDA) filing with the FDA. This agreement builds on a prior Master Services Agreement and underscores BioCorRx's commitment to advancing its treatment for opioid use disorder. The project has significant backing from the National Institute on Drug Abuse, and human trials for BICX104 are set to begin soon.
BioCorRx Inc. (OTCQB: BICX) announced it has received a $3.5 million grant from the National Institute on Drug Abuse (NIDA) to commence a first-in-human clinical trial for BICX104, an implantable biodegradable naltrexone pellet aimed at treating opioid use disorder. This funding builds on a total of $5.7 million received for a prior phase. FDA clearance has been obtained to begin trials this year, which will evaluate the pellet's safety, longevity, and tolerability. The company underscores the significance of this milestone in advancing its product toward market availability.
BioCorRx Inc. (OTCQB: BICX) announced a significant milestone in its business update for Q2 2021. The company received FDA clearance to initiate human trials for BICX104, an implantable pellet designed for opioid use disorder. This trial aims to evaluate the safety, longevity, and tolerability of BICX104, with potential dual indications for both opioid and alcohol use disorders. Additionally, the firm expanded its Scientific Advisory Board with four new members to support the upcoming trials. The company emphasizes the urgent need for effective treatment amidst the ongoing drug overdose epidemic.
BioCorRx (OTCQB: BICX) announced the addition of four new members to its Scientific Advisory Board, increasing the total to seven. The new advisors, including Dr. Ashok Kumar, Michael Howcroft, Priya Jambhekar, and Dr. Jeff Witkin, bring extensive experience in drug development and regulatory affairs. Their expertise aims to support the advancement of BICX104, an implantable naltrexone pellet for opioid use disorder, as the company navigates urgent treatment needs exacerbated by the COVID-19 pandemic. CEO Lourdes Felix expressed optimism about their contributions to improving treatment programs.
BioCorRx Inc. (OTCQB: BICX) reported significant advancements as of May 18, 2021. The company received FDA clearance to initiate human trials for BICX104, a gradual release implantable pellet aimed at treating opioid use disorder. Aiming to commence trials later this year, BioCorRx is also focused on its Beat Addiction Recovery program, combining cognitive-behavioral therapy with medication-assisted treatment. This comes amid rising substance abuse challenges exacerbated by COVID-19.
BioCorRx (OTCQB: BICX) announced FDA clearance to proceed with human trials for BICX104, an implantable naltrexone pellet targeting Opioid Use Disorder (OUD). The clinical trial, set to begin later this year, follows an IND submission to the FDA and an earlier pre-IND meeting where a potential dual indication for OUD and Alcohol Use Disorder (AUD) was discussed. With over 81,000 drug overdose deaths reported in the U.S. during the past year, this development is positioned as a critical response to the ongoing opioid crisis.
FAQ
What is the current stock price of Biocorrx (BICX)?
What is the market cap of Biocorrx (BICX)?
What does BioCorRx Inc. specialize in?
What is the BioCorRx Recovery Program?
What is BICX104?
How does BioCorRx address obesity?
What makes BioCorRx unique in the addiction treatment market?
What partnerships has BioCorRx formed to advance its treatments?
What challenges does BioCorRx aim to address in addiction treatment?
Does BioCorRx have any patented technologies?
What is the significance of the NIH HEAL Initiative® for BioCorRx?
How does BioCorRx contribute to public health?
